2022
CDX-6512 Received Orphan Drug Designation For Homocystinuria
seqWell - Partnered in the Genomics and NGS Market
2021
Launched Codex® HiTemp Reverse Transcriptase
Kalsec – Collaboration For Enzyme Supply In Production Of Clean-Label Beverage Ingredient
Improved Enzymes To Further Enhance Tate & Lyle’s Stevia And Allulose Production
2020
Molecular Assemblies – Partnered On Enzymatic DNA Synthesis
Launched Codex® HiFi DNA Polymerase & Codex® HiCap RNA Polymerase
Takeda – Gene Therapy Collaboration And License Agreement
Extended Biotherapeutics Partnering Deal With Nestlé Health Science
2019
Evo T4 DNA Ligase For Next Gen Sequencing Licensed To Roche
Novartis CodeEvolver® Platform License
First Successful Clinical Trial Completed: CDX-6114 For PKU
2018
Commercialized Enzymes For Tate & Lyle Tasteva M® Stevia Sweetener
2017
First Partnering Deal In Biotherapeutics With Nestlé Health Science
2016
First Commercial Enzyme Sold To Food Industry With Tate & Lyle
2015
Merck – CodeEvolver® Platform License
2014
GlaxoSmithKline – CodeEvolver® Platform License
2012
Merck – FDA Approval For Sitagliptin API Process Using CDX-017
2010
Codexis IPO On Nasdaq
2002
Codexis Spun-Out From Maxygen